Frontier Pharma: Obesity Identifying and Commercializing First-in-Class Innovation is a new market research publication announced by Reportstack. Despite the market's clinical and regulatory challenges, the ​obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. A total of 248 pipeline products are undergoing active development for obesity, with the vast majority currently in early-stage development. Analysis shows that 39% of the products with disclosed molecular targets are first-in-class: an indicator of a highly innovative pipeline. Although most target gut hormone receptors, the remainder target a wide range of processes thought to be dysregulated in obesity, such as angiogenesis, insulin signaling, inflammation, fat absorption, lipid synthesis, and metabolism. The current understanding of the disease combined with evidence from studies indicates that dysregulation in feeding centers in the hypothalamus and the hormonal regulation of energy balance, thermogenesis, and adipokines can contribute to an imbalance between energy intake and expenditure in obesity, and that all of these processes are interconnected.Analysis shows that only seven first-in-class products that are currently in development have been previously involved in strategic consolidations between 2006 and September 2015, meaning that a vast majority of the first-in-class products are potentially available for licensing and co-development deals. Analysis of licensing deals relevant to obesity indicates that first-in-class deals are more likely to be made in earlier stages of development than their non-first-in-class counterparts. This is also supported by industry-wide deals analysis showing that first-in-deals generally occur earlier and command a higher deal value than non-first-in-class deals, reflecting companies' willingness to invest despite the potentially high-risk profile of first-in-class products.Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to improve weight loss in order to significantly reduce obesity-associated health risks in obese patients. However, the use of currently available anti-obesity drugs is largely limited by poor long-term safety and a modest weight loss effect. Despite substantial clinical and regulatory challenges, the early-stage obesity pipeline remains robust, containing a high level of first-in-class innovation that has the potential to be translated into effective and safe weight loss treatments.

Complete report available @ ​Frontier Pharma: Obesity Identifying and Commercializing First-in-Class Innovation.

Scope

Historically, the obesity market has suffered from long-term safety concerns and modest efficacy with current treatments, both of which contribute to the low prescription rate and limited widespread use

Analysis reveals a high level of innovation and diversity in the pipeline, with 75 first-in-class programs identified to act on 60 unique molecular targets

Some first-in-class targets are deemed more likely to be developed into marketable treatments than others, having demonstrated substantial body weight reduction in Preclinical studies and addressing multiple mechanisms underpinning the development of obesity 

Deals involving first-in-class obesity products are more likely to be made in earlier stages of development than non-first-in-class deals, supported by industry-wide analysis

This report will allow you to:

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the available treatment options and their limitations in terms of safety and efficacy.

Visualize the composition of the obesity market to highlight the current unmet needs in order to gain a competitive understanding of the key opportunities.

Analyze the obesity pipeline and stratify by stage of development, molecule type, and molecular target; the diversity of molecular targets in the pipeline is extremely encouraging as obesity is characterized by the complex interplay between central and peripheral mechanisms.

Assess the therapeutic potential of first-in-class targets using a proprietary matrix that assesses and ranks first-in-class products according to clinical potential.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###